Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha inhibitors (e.g., infliximab [J&J Innovative Medicine’s Remicade, biosimilars], adalimumab [AbbVie / Eisai’s Humira, biosimilars]) and the non-TNF biologics (i.e., Takeda’s Entyvio and J&J Innovative Medicine’s Stelara) have transformed the treatment of CD, especially for moderate to severe disease, despite these drugs’ limitations in efficacy and safety. The recent approvals and emergence of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., AbbVie’s Skyrizi and Rinvoq, Eli Lilly’s Omvoh, J&J Innovative Medicine’s Tremfya) will further enhance treatment and increase market competition. Sales growth will be constrained by factors including the continuing generic erosion of conventional agents and the availability of biosimilars of TNF-alpha inhibitors and IL-12/23 inhibitors.

QUESTIONS ANSWERED

• What are KOLs’ opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio) for CD? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
• What are KOLs’ views on recently approved and emerging therapies (e.g., Skyrizi, Rinvoq, Omvoh, Tremfya) for CD? What impact will the oral therapies have on the CD treatment algorithm?
• Which emerging agents are likely to be the most successful targeting TNF-refractory patients and experiencing uptake in the CD market?
• How will the market evolve over the next 10 years?

CONTENT HIGHLIGHTS

Geographies: United States, EU5, Japan.

Primary research: 26 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of CD by country, segmented by disease activity.

Forecast: 10-year, annualized, drug-level sales and patient share of key CD therapies through 2034, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and late-phase emerging therapies.

PRODUCT DESCRIPTION

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.